

Steven A Stacker

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9142652/publications.pdf>

Version: 2024-02-01

134
papers

14,156
citations

22153

59
h-index

19749

117
g-index

136
all docs

136
docs citations

136
times ranked

12875
citing authors

#	ARTICLE	IF	CITATIONS
1	VEGF-D promotes the metastatic spread of tumor cells via the lymphatics. <i>Nature Medicine</i> , 2001, 7, 186-191.	30.7	1,113
2	Lymphangiogenesis and cancer metastasis. <i>Nature Reviews Cancer</i> , 2002, 2, 573-583.	28.4	729
3	Multiple defects in the immune system of Lyn-deficient mice, culminating in autoimmune disease. <i>Cell</i> , 1995, 83, 301-311.	28.9	673
4	Lymphangiogenesis and lymphatic vessel remodelling in cancer. <i>Nature Reviews Cancer</i> , 2014, 14, 159-172.	28.4	621
5	Signalling via vascular endothelial growth factor receptor-3 is sufficient for lymphangiogenesis in transgenic mice. <i>EMBO Journal</i> , 2001, 20, 1223-1231.	7.8	583
6	Sox18 induces development of the lymphatic vasculature in mice. <i>Nature</i> , 2008, 456, 643-647.	27.8	483
7	Pathogenesis of persistent lymphatic vessel hyperplasia in chronic airway inflammation. <i>Journal of Clinical Investigation</i> , 2005, 115, 247-257.	8.2	475
8	Consensus guidelines for the use and interpretation of angiogenesis assays. <i>Angiogenesis</i> , 2018, 21, 425-532.	7.2	429
9	VEGF-D Is the Strongest Angiogenic and Lymphangiogenic Effector Among VEGFs Delivered Into Skeletal Muscle via Adenoviruses. <i>Circulation Research</i> , 2003, 92, 1098-1106.	4.5	374
10	Pathogenesis of persistent lymphatic vessel hyperplasia in chronic airway inflammation. <i>Journal of Clinical Investigation</i> , 2005, 115, 247-257.	8.2	326
11	VEGF β and VEGF δ expression in neuroendocrine cells and their receptor, VEGFR β , in fenestrated blood vessels in human tissues. <i>FASEB Journal</i> , 2000, 14, 2087-2096.	0.5	299
12	Focus on lymphangiogenesis in tumor metastasis. <i>Cancer Cell</i> , 2005, 7, 121-127.	16.8	291
13	Biosynthesis of Vascular Endothelial Growth Factor-D Involves Proteolytic Processing Which Generates Non-covalent Homodimers. <i>Journal of Biological Chemistry</i> , 1999, 274, 32127-32136.	3.4	281
14	The role of tumor lymphangiogenesis in metastatic spread. <i>FASEB Journal</i> , 2002, 16, 922-934.	0.5	264
15	VEGF-D Promotes Tumor Metastasis by Regulating Prostaglandins Produced by the Collecting Lymphatic Endothelium. <i>Cancer Cell</i> , 2012, 21, 181-195.	16.8	244
16	Vascular Endothelial Growth Factor D Is Dispensable for Development of the Lymphatic System. <i>Molecular and Cellular Biology</i> , 2005, 25, 2441-2449.	2.3	232
17	Chronic stress in mice remodels lymph vasculature to promote tumour cell dissemination. <i>Nature Communications</i> , 2016, 7, 10634.	12.8	232
18	Molecular Control of Lymphatic Metastasis. <i>Annals of the New York Academy of Sciences</i> , 2008, 1131, 225-234.	3.8	229

#	ARTICLE	IF	CITATIONS
19	The Wnt Receptor Ryk Is Required for Wnt5a-Mediated Axon Guidance on the Contralateral Side of the Corpus Callosum. <i>Journal of Neuroscience</i> , 2006, 26, 5840-5848.	3.6	216
20	Plasmin Activates the Lymphangiogenic Growth Factors VEGF-C and VEGF-D. <i>Journal of Experimental Medicine</i> , 2003, 198, 863-868.	8.5	184
21	Adenoviral Catheter-Mediated Intramyocardial Gene Transfer Using the Mature Form of Vascular Endothelial Growth Factor-D Induces Transmural Angiogenesis in Porcine Heart. <i>Circulation</i> , 2004, 109, 1029-1035.	1.6	182
22	Deletion of Vascular Endothelial Growth Factor C (VEGF-C) and VEGF-D Is Not Equivalent to VEGF Receptor 3 Deletion in Mouse Embryos. <i>Molecular and Cellular Biology</i> , 2008, 28, 4843-4850.	2.3	174
23	Ryk-deficient mice exhibit craniofacial defects associated with perturbed Eph receptor crosstalk. <i>Nature Genetics</i> , 2000, 25, 414-418.	21.4	157
24	The Specificity of Receptor Binding by Vascular Endothelial Growth Factor-D Is Different in Mouse and Man. <i>Journal of Biological Chemistry</i> , 2001, 276, 19166-19171.	3.4	152
25	Lymphatic vessels in cancer metastasis: bridging the gaps. <i>Carcinogenesis</i> , 2006, 27, 1729-1738.	2.8	150
26	Targeting lymphangiogenesis to prevent tumour metastasis. <i>British Journal of Cancer</i> , 2006, 94, 1355-1360.	6.4	148
27	Ccbe1 regulates Vegfc-mediated induction of Vegfr3 signaling during embryonic lymphangiogenesis. <i>Development (Cambridge)</i> , 2014, 141, 1239-1249.	2.5	145
28	Molecular regulation of the VEGF family "inducers of angiogenesis and lymphangiogenesis. <i>Apmis</i> , 2004, 112, 463-480.	2.0	139
29	The Role of the Tumor Vasculature in the Host Immune Response: Implications for Therapeutic Strategies Targeting the Tumor Microenvironment. <i>Frontiers in Immunology</i> , 2016, 7, 621.	4.8	132
30	Localization of vascular endothelial growth factor-D in malignant melanoma suggests a role in tumour angiogenesis. <i>Journal of Pathology</i> , 2001, 193, 147-154.	4.5	130
31	Tumor lymphangiogenesis and metastatic spread "New players begin to emerge. <i>International Journal of Cancer</i> , 2006, 119, 1755-1760.	5.1	126
32	Lymphangiogenic Growth Factor Responsiveness Is Modulated by Postnatal Lymphatic Vessel Maturation. <i>American Journal of Pathology</i> , 2006, 169, 708-718.	3.8	125
33	Emerging Roles for VEGF-D in Human Disease. <i>Biomolecules</i> , 2018, 8, 1.	4.0	125
34	Viral Vascular Endothelial Growth Factor Plays a Critical Role in Orf Virus Infection. <i>Journal of Virology</i> , 2000, 74, 10699-10706.	3.4	123
35	Distinct Roles of Vascular Endothelial Growth Factor-D in Lymphangiogenesis and Metastasis. <i>American Journal of Pathology</i> , 2007, 170, 1348-1361.	3.8	119
36	Tissues in Different Anatomical Sites Can Sculpt and Vary the Tumor Microenvironment to Affect Responses to Therapy. <i>Molecular Therapy</i> , 2014, 22, 18-27.	8.2	112

#	ARTICLE	IF	CITATIONS
37	EGFR blockade with ZD1839 (â€œIressaâ€œ) potentiates the antitumor effects of single and multiple fractions of ionizing radiation in human A431 squamous cell carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2003, 55, 713-723.	0.8	110
38	The Wnt Coreceptor Ryk Regulates Wnt/Planar Cell Polarity by Modulating the Degradation of the Core Planar Cell Polarity Component Vangl2. <i>Journal of Biological Chemistry</i> , 2012, 287, 44518-44525.	3.4	110
39	The vascular endothelial growth factor family; proteins which guide the development of the vasculature. <i>International Journal of Experimental Pathology</i> , 2002, 79, 255-265.	1.3	105
40	Adenovirus encoding vascular endothelial growth factorâ€œD induces tissue-specific vascular patterns in vivo. <i>Blood</i> , 2002, 99, 4434-4442.	1.4	102
41	Expression of Vascular Endothelial Growth Factor Receptor-3 by Lymphatic Endothelial Cells Is Associated with Lymph Node Metastasis in Prostate Cancer. <i>Clinical Cancer Research</i> , 2004, 10, 5137-5144.	7.0	102
42	Monoclonal antibodies to vascular endothelial growth factor-D block its interactions with both VEGF receptor-2 and VEGF receptor-3. <i>FEBS Journal</i> , 2000, 267, 2505-2515.	0.2	101
43	Proprotein convertases promote processing of VEGFâ€œD, a critical step for binding the angiogenic receptor VEGFRâ€œ2. <i>FASEB Journal</i> , 2007, 21, 1088-1098.	0.5	100
44	A Mutant Form of Vascular Endothelial Growth Factor (VEGF) That Lacks VEGF Receptor-2 Activation Retains the Ability to Induce Vascular Permeability. <i>Journal of Biological Chemistry</i> , 1999, 274, 34884-34892.	3.4	96
45	Molecular control of lymphangiogenesis. <i>BioEssays</i> , 2002, 24, 1030-1040.	2.5	90
46	The evolving role of lymphatics in cancer metastasis. <i>Current Opinion in Immunology</i> , 2018, 53, 64-73.	5.5	88
47	Wnt5a Regulates Midbrain Dopaminergic Axon Growth and Guidance. <i>PLoS ONE</i> , 2011, 6, e18373.	2.5	86
48	Mutagenesis and selection of PDZ domains that bind new protein targets. <i>Nature Biotechnology</i> , 1999, 17, 170-175.	17.5	84
49	The Wnt Receptor Ryk Plays a Role in Mammalian Planar Cell Polarity Signaling. <i>Journal of Biological Chemistry</i> , 2012, 287, 29312-29323.	3.4	83
50	Genetic Dissection of Differential Signaling Threshold Requirements for the Wnt/ β -Catenin Pathway In Vivo. <i>PLoS Genetics</i> , 2010, 6, e1000816.	3.5	81
51	Angiogenic Responses of Vascular Endothelial Growth Factors in Periadventitial Tissue. <i>Human Gene Therapy</i> , 2003, 14, 1451-1462.	2.7	75
52	Placenta Growth Factor and Vascular Endothelial Growth Factor are Co-Expressed During Early Embryonic Development. <i>Growth Factors</i> , 1997, 15, 69-80.	1.7	70
53	VEGF-D is an X-linked/AP-1 Regulated Putative Onco-angiogen in Human Glioblastoma Multiforme. <i>Molecular Medicine</i> , 2001, 7, 598-608.	4.4	69
54	VEGFD regulates blood vascular development by modulating SOX18 activity. <i>Blood</i> , 2014, 123, 1102-1112.	1.4	65

#	ARTICLE	IF	CITATIONS
55	Lymphangiogenic growth factors as markers of tumor metastasis. <i>Apmis</i> , 2004, 112, 539-549.	2.0	64
56	Viral Vascular Endothelial Growth Factors Vary Extensively in Amino Acid Sequence, Receptor-binding Specificities, and the Ability to Induce Vascular Permeability yet Are Uniformly Active Mitogens. <i>Journal of Biological Chemistry</i> , 2003, 278, 38004-38014.	3.4	63
57	Vascular endothelial growth factor-D expression in human atherosclerotic lesions. <i>Cardiovascular Research</i> , 2003, 59, 971-979.	3.8	63
58	Where to now with the VEGF signalling pathway in cancer?. <i>Chinese Journal of Cancer</i> , 2013, 32, 297-302.	4.9	63
59	A New Breast Carcinoma Antigen Defined by a Monoclonal Antibody ² . <i>Journal of the National Cancer Institute</i> , 1985, 75, 801-811.	6.3	61
60	Multiple Forms of Mouse Vascular Endothelial Growth Factor-D Are Generated by RNA Splicing and Proteolysis. <i>Journal of Biological Chemistry</i> , 2001, 276, 44307-44314.	3.4	59
61	A Role for Bone Morphogenetic Protein-4 in Lymph Node Vascular Remodeling and Primary Tumor Growth. <i>Cancer Research</i> , 2011, 71, 6547-6557.	0.9	59
62	Vegfd modulates both angiogenesis and lymphangiogenesis during zebrafish embryonic development. <i>Development (Cambridge)</i> , 2017, 144, 507-518.	2.5	56
63	The Angiogenic and Lymphangiogenic Factor Vascular Endothelial Growth Factor-D Exhibits a Paracrine Mode of Action in Cancer. <i>Growth Factors</i> , 2002, 20, 99-107.	1.7	54
64	The Vascular Endothelial Growth Factor Family: Signalling for Vascular Development. <i>Growth Factors</i> , 1999, 17, 1-11.	1.7	52
65	From Anti-Angiogenesis to Anti-Lymphangiogenesis: Emerging Trends in Cancer Therapy. <i>Lymphatic Research and Biology</i> , 2008, 6, 165-172.	1.1	52
66	The Interplay Between Lymphatic Vessels and Chemokines. <i>Frontiers in Immunology</i> , 2019, 10, 518.	4.8	52
67	Renal ischemia-reperfusion increases endothelial VEGFR-2 without increasing VEGF or VEGFR-1 expression. <i>Kidney International</i> , 2002, 61, 1696-1706.	5.2	49
68	The connection between lymphangiogenic signalling and prostaglandin biology: A missing link in the metastatic pathway. <i>Oncotarget</i> , 2012, 3, 893-906.	1.8	47
69	Pseudocowpox virus Encodes a Homolog of Vascular Endothelial Growth Factor. <i>Virology</i> , 2003, 305, 298-309.	2.4	44
70	The Wnt Receptor Ryk Reduces Neuronal and Cell Survival Capacity by Repressing FOXO Activity During the Early Phases of Mutant Huntingtin Pathogenicity. <i>PLoS Biology</i> , 2014, 12, e1001895.	5.6	42
71	The biochemistry, signalling and disease relevance of RYK and other WNT-binding receptor tyrosine kinases. <i>Growth Factors</i> , 2018, 36, 15-40.	1.7	42
72	Comparison of mammary serum antigen (MSA) and CA15-3 levels in the serum of patients with breast cancer. <i>British Journal of Cancer</i> , 1987, 56, 820-824.	6.4	39

#	ARTICLE	IF	CITATIONS
73	Importance of Wnt Signaling in the Tumor Stroma Microenvironment. <i>Current Cancer Drug Targets</i> , 2008, 8, 454-465.	1.6	39
74	Molecular Targeting of Lymphatics for Therapy. <i>Current Pharmaceutical Design</i> , 2004, 10, 65-74.	1.9	37
75	Signaling for lymphangiogenesis via VEGFR-3 is required for the early events of metastasis. <i>Clinical and Experimental Metastasis</i> , 2013, 30, 819-832.	3.3	37
76	Genome-wide functional analysis reveals central signaling regulators of lymphatic endothelial cell migration and remodeling. <i>Science Signaling</i> , 2017, 10, .	3.6	37
77	Revelations of the RYK receptor. <i>BioEssays</i> , 2000, 23, 34-45.	2.5	36
78	A system for quantifying the patterning of the lymphatic vasculature. <i>Growth Factors</i> , 2007, 25, 417-425.	1.7	36
79	Vascular Endothelial Growth Factor-d Modulates Caliber and Function of Initial Lymphatics in the Dermis. <i>Journal of Investigative Dermatology</i> , 2013, 133, 2074-2084.	0.7	36
80	Arap3 is dysregulated in a mouse model of hypotrichosisâ€“lymphedemaâ€“telangiectasia and regulates lymphatic vascular development. <i>Human Molecular Genetics</i> , 2014, 23, 1286-1297.	2.9	36
81	Tie2 Receptor Expression and Phosphorylation in Cultured Cells and Mouse Tissues. <i>FEBS Journal</i> , 1997, 244, 774-779.	0.2	35
82	Differential Receptor Binding and Regulatory Mechanisms for the Lymphangiogenic Growth Factors Vascular Endothelial Growth Factor (VEGF)-C and -D. <i>Journal of Biological Chemistry</i> , 2016, 291, 27265-27278.	3.4	35
83	CCL27/CCL28â€“CCR10 Chemokine Signaling Mediates Migration of Lymphatic Endothelial Cells. <i>Cancer Research</i> , 2019, 79, 1558-1572.	0.9	33
84	Proteolytic processing of vascular endothelial growth factorâ€“D is essential for its capacity to promote the growth and spread of cancer. <i>FASEB Journal</i> , 2011, 25, 2615-2625.	0.5	32
85	Vascular endothelial growth factor-D: signaling mechanisms, biology, and clinical relevance. <i>Growth Factors</i> , 2012, 30, 283-296.	1.7	32
86	Non-canonical Wnt Signaling through Ryk Regulates the Generation of Somatostatin- and Parvalbumin-Expressing Cortical Interneurons. <i>Neuron</i> , 2019, 103, 853-864.e4.	8.1	31
87	Lymphatic endothelium: An important interactive surface for malignant cells. <i>Pulmonary Pharmacology and Therapeutics</i> , 2006, 19, 51-60.	2.6	30
88	Lymphatic vessel density in primary melanomas predicts sentinel lymph node status and risk of metastasis. <i>Histopathology</i> , 2012, 61, 702-710.	2.9	29
89	Vascular endothelial growth factor-D induces lymphangiogenesis and lymphatic metastasis in models of ductal pancreatic cancer. <i>International Journal of Oncology</i> , 2005, 27, 669-79.	3.3	29
90	Ryk, a Receptor Regulating Wnt5a-Mediated Neurogenesis and Axon Morphogenesis of Ventral Midbrain Dopaminergic Neurons. <i>Stem Cells and Development</i> , 2013, 22, 2132-2144.	2.1	28

#	ARTICLE	IF	CITATIONS
91	Regenerating lizard tails: A new model for investigating lymphangiogenesis. <i>FASEB Journal</i> , 2003, 17, 1-13.	0.5	27
92	Tumor location and nature of lymphatic vessels are key determinants of cancer metastasis. <i>Clinical and Experimental Metastasis</i> , 2013, 30, 345-356.	3.3	26
93	The Propeptides of VEGF-D Determine Heparin Binding, Receptor Heterodimerization, and Effects on Tumor Biology. <i>Journal of Biological Chemistry</i> , 2013, 288, 8176-8186.	3.4	25
94	Genomic Structure and Expression of the Mouse Growth Factor Receptor Related to Tyrosine Kinases (Ryk). <i>Journal of Biological Chemistry</i> , 1999, 274, 7379-7390.	3.4	24
95	VEGF-D promotes pulmonary oedema in hyperoxic acute lung injury. <i>Journal of Pathology</i> , 2016, 239, 152-161.	4.5	24
96	Mechanisms of Lymphangiogenesis: Targets for Blocking the Metastatic Spread of Cancer. <i>Current Cancer Drug Targets</i> , 2005, 5, 561-571.	1.6	23
97	Systematic high-content genome-wide RNAi screens of endothelial cell migration and morphology. <i>Scientific Data</i> , 2017, 4, 170009.	5.3	23
98	Evolutionary Differences in the Vegf/Vegfr Code Reveal Organotypic Roles for the Endothelial Cell Receptor Kdr in Developmental Lymphangiogenesis. <i>Cell Reports</i> , 2019, 28, 2023-2036.e4.	6.4	23
99	A Fully Human Inhibitory Monoclonal Antibody to the Wnt Receptor RYK. <i>PLoS ONE</i> , 2013, 8, e75447.	2.5	22
100	Remodeling of the Lymphatic Vasculature during Mouse Mammary Gland Morphogenesis Is Mediated via Epithelial-Derived Lymphangiogenic Stimuli. <i>American Journal of Pathology</i> , 2012, 181, 2225-2238.	3.8	20
101	Molecular Pathways for Lymphangiogenesis and their Role in Human Disease. <i>Novartis Foundation Symposium</i> , 2006, 281, 38-49.	1.1	16
102	The VD1 Neutralizing Antibody to Vascular Endothelial Growth Factor-D: Binding Epitope and Relationship to Receptor Binding. <i>Journal of Molecular Biology</i> , 2011, 407, 581-593.	4.2	15
103	Preparation of human vascular endothelial growth factor-D for structural and preclinical therapeutic studies. <i>Protein Expression and Purification</i> , 2012, 82, 232-239.	1.3	15
104	Control of Gene Expression by Exosome-Derived Non-Coding RNAs in Cancer Angiogenesis and Lymphangiogenesis. <i>Biomolecules</i> , 2021, 11, 249.	4.0	15
105	Targeting lymphatic vessel functions through tyrosine kinases. <i>Journal of Angiogenesis Research</i> , 2010, 2, 13.	2.9	14
106	Vascular endothelial growth factor-D over-expressing tumor cells induce differential effects on uterine vasculature in a mouse model of endometrial cancer. <i>Reproductive Biology and Endocrinology</i> , 2010, 8, 84.	3.3	13
107	Lymphovascular and neural regulation of metastasis: Shared tumour signalling pathways and novel therapeutic approaches. <i>Bailliere's Best Practice and Research in Clinical Anaesthesiology</i> , 2013, 27, 409-425.	4.0	13
108	Wnt5a induces Ryk-dependent and -independent effects on callosal axon and dendrite growth. <i>Growth Factors</i> , 2014, 32, 11-17.	1.7	12

#	ARTICLE	IF	CITATIONS
109	A Simple Bioassay for the Evaluation of Vascular Endothelial Growth Factors. <i>Journal of Visualized Experiments</i> , 2016, , .	0.3	10
110	Towards the biomarker-guided rational use of antiangiogenic agents in the treatment of metastatic colorectal cancer. <i>Colorectal Cancer</i> , 2012, 1, 149-161.	0.8	7
111	Exit Stage Left: A Tumor Cell's Journey from Lymph Node to Beyond. <i>Trends in Cancer</i> , 2018, 4, 519-522.	7.4	7
112	A Serum Test for the Diagnosis and Monitoring the Progress of Breast Cancer. , 1987, , 217-227.		7
113	Brain Vascular Microenvironments in Cancer Metastasis. <i>Biomolecules</i> , 2022, 12, 401.	4.0	7
114	Exploring the role of endothelium in the tumour response to anti-angiogenic therapy. <i>Biochemical Society Transactions</i> , 2014, 42, 1569-1575.	3.4	6
115	The RYK Receptor Family. , 2015, , 685-741.		6
116	A Three-Dimensional Lymphatic Endothelial Cell Tube Formation Assay to Identify Novel Kinases Involved in Lymphatic Vessel Remodeling. <i>Assay and Drug Development Technologies</i> , 2017, 15, 30-43.	1.2	6
117	The fibrinolysis inhibitor α_2 -antiplasmin restricts lymphatic remodelling and metastasis in a mouse model of cancer. <i>Growth Factors</i> , 2017, 35, 61-75.	1.7	6
118	Three-dimensional CRISPR screening reveals epigenetic interaction with anti-angiogenic therapy. <i>Communications Biology</i> , 2021, 4, 878.	4.4	6
119	Editorial [Hot Topic:Targeting Tumor Stroma (Guest Editors: Marc G. Achen and Steven A. Stacker)]. <i>Current Cancer Drug Targets</i> , 2008, 8, 446-446.	1.6	5
120	Deficiency of the Wnt receptor Ryk causes multiple cardiac and outflow tract defects. <i>Growth Factors</i> , 2018, 36, 58-68.	1.7	5
121	Expression and purification of bioactive, low-endotoxin recombinant human vitronectin. <i>BioTechniques</i> , 2014, 56, 331-3.	1.8	4
122	Counting nuclei released from microcarrier-based cultures using pro-fluorescent nucleic acid stains and volumetric flow cytometry. <i>BioTechniques</i> , 2017, 63, 34-36.	1.8	4
123	RYK-mediated filopodial pathfinding facilitates midgut elongation. <i>Development (Cambridge)</i> , 2020, 147, .	2.5	4
124	Growth factors: the journey continues. <i>Growth Factors</i> , 2016, 34, 1-4.	1.7	3
125	Soothing a Broken Heart. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2020, 40, 1611-1613.	2.4	3
126	<i>Prkd1</i> and <i>Wnt5a</i> genetically interact to control lymphatic vascular morphogenesis in mice. <i>Developmental Dynamics</i> , 2022, 251, 336-349.	1.8	3

#	ARTICLE	IF	CITATIONS
127	VEGF receptors branch into new areas. <i>Blood</i> , 2004, 103, 4379-4380.	1.4	2
128	Plasmin activates VEGF-C and VEGF-D. <i>International Congress Series</i> , 2004, 1262, 79-82.	0.2	1
129	Lymphangiogenesis in Cancer Metastasis. <i>Cancer Metastasis - Biology and Treatment</i> , 2009, , .	0.1	1
130	The Lymphatics: On the Route to Cancer Metastasis. , 0, , 237-254.		0
131	Inhibitors of Angiogenesis. , 2002, , 261-292.		0
132	Vascular Endothelial Growth Factor D (VEGF-D). , 2003, , 559-564.		0
133	Lymphangiogenesis in Health and Disease â€“ An Overview. <i>Cancer Metastasis - Biology and Treatment</i> , 2009, , 1-9.	0.1	0
134	Non-Canonical Wnt-Signaling through <i>Ryk</i> Regulates the Generation of Somatostatin- and Parvalbumin-Expressing Cortical Interneurons. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0